

# 155 Infective Endocarditis

Adolf W. Karchmer


The prototypic lesion of infective endocarditis, the *vegetation* (Fig. 155-1), is a mass of platelets, fibrin, microcolonies of microorganisms, and scant inflammatory cells. Infection most commonly involves heart valves but may also occur on the low-pressure side of a ventricular septal defect, on mural endocardium damaged by aberrant jets of blood or foreign bodies, or on intracardiac devices themselves. The analogous process involving arteriovenous shunts, arterio-arterial shunts (patent ductus arteriosus), or a coarctation of the aorta is called *infective endarteritis*.

Endocarditis can be classified according to the temporal evolution of disease, the site of infection, the cause of infection, or the predisposing risk factor (e.g., injection drug use). While each classification criterion provides therapeutic and prognostic insight, none is sufficient alone. *Acute endocarditis* is a hectically febrile illness that rapidly damages cardiac structures, seeds extracardiac sites, and, if untreated, progresses to death within weeks. *Subacute endocarditis* follows an indolent course; causes structural cardiac damage only slowly, if at all; rarely metastasizes; and is gradually progressive unless complicated by a major embolic event or a ruptured mycotic aneurysm.

In developed countries, the incidence of endocarditis ranges from 4 to 7 cases per 100,000 population per year and has remained relatively stable during recent decades. While congenital heart diseases remain a constant predisposition, predisposing conditions in developed countries have shifted from chronic rheumatic heart disease (still a common predisposition in developing countries) to illicit IV drug use, degenerative valve disease, and intracardiac devices. The incidence of endocarditis is notably increased among the elderly. In developed countries, 25–35% of cases of native valve endocarditis (NVE) are associated with health care, and 16–30% of all cases of endocarditis involve prosthetic valves. The risk of prosthesis infection is greatest during the first 6–12 months after valve replacement; gradually declines to a low, stable rate thereafter; and is similar for mechanical and bioprosthetic devices. The incidence of endocarditis involving cardiovascular implantable electronic devices (CIED), primarily permanent pacemakers and implantable cardioverter-defibrillators, ranges from 0.5 to 1.14 cases per 1000 device recipients and is higher among patients with an implantable cardioverter-defibrillator than among those with a permanent pacemaker.

## ETIOLOGY

Although many species of bacteria and fungi cause sporadic episodes of endocarditis, a few bacterial species cause the majority of cases (Table 155-1). The oral cavity, skin, and upper respiratory tract are



**FIGURE 155-1** Vegetations (arrows) due to viridans streptococcal endocarditis involving the mitral valve.

the respective primary portals for viridans streptococci, staphylococci, and HACEK organisms (*Haemophilus* species, *Aggregatibacter aphrophilus*, *A. actinomycetemcomitans*, *Cardiobacterium* species, *Eikenella* species, and *Kingella* species). *Streptococcus gallolyticus* subspecies *gallolyticus* (formerly *S. bovis* biotype 1) originates from the gastrointestinal tract, where it is associated with polyps and colonic tumors, and enterococci enter the bloodstream from the genitourinary tract. Health care–associated NVE, most commonly caused by *Staphylococcus aureus*, coagulase-negative staphylococci (CoNS), and enterococci, may have either a nosocomial onset (55%) or a community onset (45%); community-onset cases develop in patients who have had extensive contact with the health care system over the preceding 90 days. Endocarditis complicates 6–25% of episodes of catheter-associated *S. aureus* bacteremia; the higher rates are detected in high-risk patients studied by transesophageal echocardiography (TEE) (see “Echocardiography,” later).

Prosthetic valve endocarditis (PVE) arising within 2 months of valve surgery is generally nosocomial, the result of intraoperative contamination of the prosthesis or a bacteremic postoperative complication. This nosocomial origin is reflected in the primary microbial causes: *S. aureus*, CoNS, facultative gram-negative bacilli, diphtheroids, and fungi. The portals of entry and organisms causing cases beginning >12 months after surgery are similar to those in community-acquired NVE. PVE due to CoNS that presents 2–12 months after surgery often represents delayed-onset nosocomial infection. Regardless of the time of onset after surgery, at least 68–85% of CoNS strains that cause PVE are resistant to methicillin.

Endocarditis related to a permanent pacemaker or an implantable cardioverter-defibrillator involves the device or the endothelium at points of device contact. Occasionally, there is concurrent aortic or mitral valve infection. One-third of cases of CIED endocarditis present within 3 months after device implantation or manipulation, one-third present at 4–12 months, and one-third present at >1 year. *S. aureus* and CoNS, both of which are commonly resistant to methicillin, cause the majority of cases.

Injection drug use–associated endocarditis, especially that involving the tricuspid valve, is commonly caused by *S. aureus*, which in many cases is resistant to methicillin. Left-sided valve infections in addicts have a more varied etiology. In addition to the usual causes of endocarditis, these cases can be due to *Pseudomonas aeruginosa* and *Candida* species, and sporadic cases can be caused by unusual organisms such as *Bacillus*, *Lactobacillus*, and *Corynebacterium* species. Polymicrobial endocarditis occurs among injection drug users. HIV infection in drug users does not significantly influence the causes of endocarditis.

From 5% to 15% of patients with endocarditis have negative blood cultures; in one-third to one-half of these cases, cultures are negative because of prior antibiotic exposure. The remainder of these patients are infected by fastidious organisms, such as nutritionally variant bacteria (now designated *Granulicatella* and *Abiotrophia* species), HACEK organisms, *Coxiella burnetii*, and *Bartonella* species. Some fastidious organisms occur in characteristic geographic settings (e.g., *C. burnetii* and *Bartonella* species in Europe, *Brucella* species in the Middle East). *Tropheryma whippelii* causes an indolent, culture-negative, afebrile form of endocarditis.

## PATHOGENESIS

The undamaged endothelium is resistant to infection by most bacteria and to thrombus formation. Endothelial injury (e.g., at the site of impact of high-velocity blood jets or on the low-pressure side of a cardiac structural lesion) allows either direct infection by virulent organisms or the development of a platelet-fibrin thrombus—a condition called *nonbacterial thrombotic endocarditis* (NBTE). This thrombus serves as a site of bacterial attachment during transient bacteremia. The cardiac conditions most commonly resulting in NBTE are mitral regurgitation, aortic stenosis, aortic regurgitation, ventricular septal defects, and complex congenital heart disease. NBTE also arises as a result of a hypercoagulable state; this gives rise to *marantic endocarditis* (uninfected vegetations seen in patients with malignancy and chronic diseases) and to bland vegetations